A panel of experts discuss the complex nature of myelodysplastic syndromes and concurrent subclassifications. At the start, we’re going to lean heavily on Dr Zeidan because we want to have a good ...

Myelodysplastic syndromes (MDS) are malignant disorders arising from hematopoietic stem cells, yet the precise epigenetic abnormalities occurring in the primitive stem cells remain poorly understood.

Myelodysplastic syndrome is an extremely heterogeneous disease, and there is no definitive cure, so these investigators wanted a better understanding of patients’ priorities regarding their care, ...

There are more treatments today than ever before to help people with ongoing conditions manage their physical symptoms. But even with these medical advances, a diagnosis of myelodysplastic syndromes ...

Published on April 01, 2026, in Volume 2, article number 19 of the journal Immunity & Inflammation, a collaborative team led ...

The classification system for this type of cancer aims to help define, diagnose, and treat the disease and improve outcomes. Myelodysplastic syndromes (MDSs), which are now also called myelodysplastic ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Probably the most critical complication in ...

Published on April 01, 2026, in Volume 2, article number 19 of the journal Immunity & Inflammation , a collaborative team led by Prof. Cao at the ...

The novel treatment elritercept received a Fast Track designation from the FDA to treat anemia in patients with MDS. For patients with lower-risk myelodysplastic syndromes (MDS), the Food and Drug ...